

Your Keywords

In addition to the RoboPICO highlighting, you can custom-add Your Keywords to have them underlined in the Abstract view.


User Keywords can be added or edited in **two places**; the list of User Keywords can be populated and edited from the Configure Screening page, and then additionally populated and edited from the Abstract View for any study within a nest.

Steps for Configuring Keyword Underlining

On the Configure Screening page


1. Go to the Configure Screening page

This is right below the “Screening” header in the AutoLit menu (see below).



2. Add Keywords to the “Your Keywords” Section

Click on “Your Keywords” in the toggle button next to Exclusion Reasons (see below). To add an exclusion reason click the “Add” button, type in your Keyword of interest and hit enter or add.



After adding a keyword, you can color code it by clicking the circle to the left of the keyword and choosing from the colors displayed. This color corresponds to the highlight color when that specific keyword is identified in an Abstract during Screening. If no color is chosen, the default is light blue.

Close

Exclusion ReasonsYour Keywords

New keyword

Add

Keyword	
Description	
Summary	

Below you can see how this looks in an Abstract during Screening.

6Levi, 2016

AbstractFull TextSupplementsRelated Reports

PubMed

Intradiscal Platelet-Rich Plasma Injection for Chronic Discogenic Low Back Pain: Preliminary Results from a Prospective Trial.

BACKGROUND Platelet-rich plasma (PRP) has been found to be effective for a variety of musculoskeletal conditions. The treatment of discogenic pain with PRP is under investigation. OBJECTIVE To assess changes in pain and function in patients with discogenic low back pain after an intradiscal injection of PRP. STUDY DESIGN Prospective trial. METHODS Patients were diagnosed with discogenic low back pain by clinical means, imaging, and exclusion of other structures. Provocation discography was used in a minority of the patients. Patients underwent a single treatment of intradiscal injection of PRP at one or multiple levels. MAIN OUTCOME MEASURES Patients were considered a categorical success if they achieved at least 50% improvement in the visual analog score and 30% decrease in the Oswestry Disability Index at 1, 2, and 6 months post-treatment. RESULTS 22 patients underwent intradiscal PRP. Nine patients underwent a single level injection, ten at 2 levels, two at 3 levels, and one at 5 levels. Categorical success rates were as follows: 1 month: 3/22 = 14% (95% CI 0% to 28%), 2 months: 7/22 = 32% (95% CI 12% to 51%), 6 months: 9/19 = 47% (95% CI 25% to 70%). CONCLUSION This trial demonstrates encouraging preliminary 6 month findings, using strict categorical success criteria, for intradiscal PRP as a treatment for presumed discogenic low back pain. Randomized placebo controlled trials are needed to further evaluate the efficacy of this treatment.

Population/ProblemInterventionOutcomeYour Keywords

652841

KeywordsBibliographic fields

Edit

About Docs SupportAutolit

ABFTTagMA ExtractAppraisal

YouAdjudicate

Full Text ReviewFull Text Uploaded!

ExcludeSearch Reasons

Select Reason

Test Reason

Not my tempo

Robot Excluded

Random Selection

Irrelevant

asdfasf

hi hello

Advance

Advance

Abstract Screenings

Tagging

Comments (0)

History

3. Delete Your Keywords

If you need to delete a Keyword after creation, you can do so by selecting the trash can icon.

Deletion of the Keywords you created on this page can also be deleted from the Abstract view.

On the Abstract View

1. Go to the Abstract View in Screening

You can also add keywords during the screening process. Whenever you come across an abstract to screen, whether in the Screening module or Study Inspector, you can add keywords on the fly.

2. Click on “Your Keywords”

<https://wiki.nested-knowledge.com/>

Printed on 2023/12/20 01:52

100 Smith, 2022

Abstract Full Text Supplements Related Reports

CT.gov

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Brief Summary: The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria. **Detailed Description:** The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab in patients with Chronic Spontaneous Urticaria. There is a screening period of up to 4 weeks, followed by a 16-week placebo-controlled treatment period (Placebo-Controlled Treatment Phase) where patients will receive either barzolvolimab at a dose level of 75mg, 150mg, or 300mg, or placebo, and then a 36-week treatment period where all patients will receive barzolvolimab. Patients who receive barzolvolimab 75mg or placebo in the placebo-controlled treatment phase will be re-randomized to receive either barzolvolimab 150mg or 300mg in the active treatment phase. **Study Type:** Interventional Actual Enrollment: 168 participants Status (as of import): Recruiting

Population/Problem Intervention Outcome **Your Keywords**

3. Type in desired keyword and hit "Add."

A modal opens with the same functions as in Configure Screening as described above including color coding and ability to edit and delete existing keywords.

Your Keywords

Close X

New keyword Add +

Keyword	
Description	
Summary	

Close

4. Any changes made here will be reflected in the abstract.

From:

<https://wiki.nested-knowledge.com/> - **Nested Knowledge**

Permanent link:

<https://wiki.nested-knowledge.com/doku.php?id=wiki:autolit:screening:keywords>Last update: **2023/12/12 21:33**